Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.

Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, Taskinen MR, Yki-Järvinen H, Smith U

Diabetes care27 Apr 2010Cited by 126 (Europe PMC)

PMID20424219PMCIDPMC2909051DOI10.2337/dc09-2361PepBankPUB-20424219

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide reduced body weight by 6% from baseline.
In plain wordsIn patients with diabetes taking metformin, body weight fell by 6% during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Body weight reduction
6%
exenatide
Source sentences
Summary
Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year.
Summary · context
Body composition was evaluated by dual-energy X-ray absorptiometry.
Report a problemFND-2042421901
02HumanRandomized controlled trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide reduced waist circumference by 5% from baseline.
In plain wordsIn patients with diabetes taking metformin, waist size fell by 5% during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Waist reduction
5%
exenatide
Source sentences
Summary
Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year.
Summary · context
Body composition was evaluated by dual-energy X-ray absorptiometry.
Report a problemFND-2042421902
03HumanRandomized controlled trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide reduced total body fat mass by 11% from baseline.
In plain wordsIn patients with diabetes taking metformin, total body fat fell by 11% during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal body fat mass
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Total fat reduction
11%
exenatide
Source sentences
Summary
Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year.
Summary · context
Body composition was evaluated by dual-energy X-ray absorptiometry.
Report a problemFND-2042421903
04HumanRandomized controlled trialEfficacy outcome
In metformin-treated patients with type 2 diabetes, exenatide reduced trunkal fat mass by 13% from baseline.
In plain wordsIn patients with diabetes taking metformin, fat in the trunk fell by 13% during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTrunkal fat mass
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Trunkal fat reduction
13%
exenatide
Source sentences
Summary
Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year.
Summary · context
Body composition was evaluated by dual-energy X-ray absorptiometry.
Report a problemFND-2042421904
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide increased adiponectin by 12%, independently of changes in fat mass and weight.
In plain wordsIn patients with diabetes, adiponectin rose by 12% with exenatide, independently of changes in fat mass and weight.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTotal adiponectin
Study
n: not reported in source
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Adiponectin increase
12%
exenatide
Source sentences
Summary
In addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive protein by 61%.
3 context sentences(design, population, supporting numbers)
Summary · context
These changes were statistically independent of the change in total body fat mass and body weight.
Summary · context
Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year.
Summary · context
Body composition was evaluated by dual-energy X-ray absorptiometry.
Report a problemFND-2042421905
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced high-sensitivity C-reactive protein by 61%, independently of changes in fat mass and weight.
In plain wordsIn patients with diabetes, this inflammation marker fell by 61% with exenatide, independently of changes in fat mass and weight.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHigh-sensitivity C-reactive protein
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
High-sensitivity CRP reduction
61%
exenatide
Source sentences
Summary
In addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive protein by 61%.
3 context sentences(design, population, supporting numbers)
Summary · context
These changes were statistically independent of the change in total body fat mass and body weight.
Summary · context
Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year.
Summary · context
Body composition was evaluated by dual-energy X-ray absorptiometry.
Report a problemFND-2042421906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT04122716

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Signe Torekovn = 215Sept 2016 to est. Nov 2021

Obesity

Trial page ClinicalTrials.govUpdated 2 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.